An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study

Summary

The primary objective is to provide continued access to PRO 140 to a subject who has completed participation in PRO140\_CD02.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications